Observational study on pulmonary hypertension in China
A Observational Study in Chinese Patients With Pulmonary Hypertension (PH)
This study is trying to gather information from a large group of people with pulmonary hypertension in China to see how to better diagnose and treat their condition over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05958901 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a large cohort of patients with pulmonary hypertension (PH) in China, along with a biological database to support precision medicine. By collecting data on patients with PH, the study seeks to optimize diagnosis and treatment options tailored to individual needs. Participants will be monitored over a period of five years to gather comprehensive information on their condition and treatment responses.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with pulmonary hypertension, characterized by a mean pulmonary artery pressure greater than 25mmHg at rest or greater than 30mmHg during exercise.
Not a fit: Patients with acute exacerbations, severe respiratory diseases, or recent significant medical interventions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and personalized treatment strategies for patients with pulmonary hypertension.
How similar studies have performed: While observational studies on pulmonary hypertension exist, this specific approach to creating a large cohort and biological database in China is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * PH group: When the mean pulmonary artery pressure is greater than 25mmHg at rest or greater than 30mmHg during exercise. * Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years. Exclusion Criteria: * Acute exacerbation in the past 3 months Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc. * Serious uncontrolled diseases thoracic or abdominal surgery in the last 3 months. * Eye surgery in the last three months. * Retinal detachment myocardial infarction in the last 3 months. * Admission to hospital for any cardiac condition in the last month. * Heart rate over 120 beats per minute. * Antibacterial chemotherapy for tuberculosis pregnant or breast feeding.
Where this trial is running
Guangzhou, Guangdong
- The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.